Vertex Pharmaceuticals (NQ:VRTX)

442.34 -1.58 (-0.36%)

Streaming Delayed Price Updated: 12:45 PM EDT, Apr 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9

...

72 73 Next >

Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week

November 08, 2025

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Biotech Sector Soars: Promising Drug Trials Ignite Investor Confidence and Spark Market Rally

November 07, 2025

The biotech sector is currently experiencing a robust rally, a significant turnaround from a period of subdued performance. This resurgence is primarily fueled by a wave of promising drug trial results...

Via MarketMinute

Topics Artificial Intelligence Intellectual Property

Earnings Scheduled For November 3, 2025 ↗

November 03, 2025

Via Benzinga

Global Markets Brace for Inflation's Enduring Grip: A November 2025 Outlook

November 07, 2025

As November 2025 unfolds, global financial markets find themselves in a complex and challenging environment, bracing for the enduring grip of inflation. Despite some signs of moderating headline...

Via MarketMinute

Topics Artificial Intelligence Bonds Economy

FDA Fast-Tracks 6 More Drugs - Obesity And Cancer Drugs Included ↗

November 07, 2025

FDA adds six drugs to its priority voucher program as CMS and the White House unveil measures to speed reviews and lower prescription costs.

Via Benzinga

2 Nasdaq 100 Stocks with Competitive Advantages and 1 Facing Challenges

November 05, 2025

While the Nasdaq 100 (^NDX) is filled with cutting-edge technology and consumer companies, not all are on solid footing. Some are dealing with declining demand, high costs, or regulatory pressures that...

Via StockStory

Palantir Weighs On Wall Street, Bitcoin Slumps 5%: What's Moving Markets Tuesday? ↗

November 04, 2025

Risk appetite cooled on Tuesday as investors interpreted the latest batch of corporate earnings as solid but not spectacular, offering a convenient excuse to take profits after strong year-to-date...

Via Benzinga

VRTX Q3 Deep Dive: New Product Launches and Pipeline Progress Shape Outlook

November 04, 2025

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) met Wall Streets revenue expectations in Q3 CY2025, with sales up 11% year on year to $3.08 billion. The company’s outlook for the full year was...

Via StockStory

Vertex Pharmaceuticals (NASDAQ:VRTX) Reports Q3 In Line With Expectations

November 03, 2025

Via StockStory

Vertex Pharma Dips Despite Quarterly Beat And Slight Guidance Book ↗

November 03, 2025

Vertex stock dipped late Monday despite better-than-expected third-quarter metrics and a slight sales guidance boost.

Via Investor's Business Daily

Vertex Reports Third Quarter 2025 Financial Results

November 03, 2025

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Vertex Pharmaceuticals Likely To Report Higher Q3 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call ↗

November 03, 2025

Via Benzinga

Nvidia, Amazon Extend Rally, Bitcoin Sinks To $107,000: What's Moving Markets Monday? ↗

November 03, 2025

Wall Street opened the week on a mixed note on Monday.

Via Benzinga

2 Healthcare Stocks for Individual Investors With a 20-Year Time Horizon ↗

November 03, 2025

These healthcare stocks are making strides in very important ways.

Via The Motley Fool

Topics Intellectual Property

Inflation-Proof Investing: Which Growth Stock Will Double Your Money in 6 Years? ↗

November 03, 2025

These are great picks with or without soaring inflation.

Via The Motley Fool

Topics Economy Government World Trade

My Top Growth Stock to Buy in November ↗

November 02, 2025

This stock isn't bulletproof. But it should be a big winner over the coming years.

Via The Motley Fool

Vertex Pharmaceuticals (VRTX) Q3 Earnings: What To Expect

November 01, 2025

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be announcing earnings results this Monday after market hours. Here’s what you need to know.

Via StockStory

How Royalty Pharma Prints Cash Without Biotech's Biggest Risks ↗

October 31, 2025

Via MarketBeat

Here's How Much $100 Invested In Vertex Pharmaceuticals 15 Years Ago Would Be Worth Today ↗

October 30, 2025

Via Benzinga

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Shows Strong Fundamentals and Bullish Technical Setup ↗

October 29, 2025

Discover how Vertex Pharmaceuticals (VRTX) combines strong fundamentals, like high profitability and no debt, with a bullish technical breakout pattern for potential growth.

Via Chartmill

If I Could Only Buy 2 Stocks in the Last Quarter of 2025, I'd Pick These ↗

October 28, 2025

These two have been neglected by Wall Street too much.

Via The Motley Fool

Vertex to Participate in the UBS Global Healthcare Conference on November 11

October 27, 2025

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Prediction: Vertex Pharmaceuticals Will Be Worth More Than Pfizer by 2030 ↗

October 27, 2025

Vertex appears to be by far the better buy right now.

Via The Motley Fool

Topics Intellectual Property

The Best Stocks to Invest $50,000 In Right Now ↗

October 24, 2025

There's no guarantee that any stock will deliver positive returns. But the odds look good for these three.

Via The Motley Fool

Topics Artificial Intelligence Energy

Vertex Presents New Data Across Portfolio of Cystic Fibrosis Medicines Including ALYFTREK® at the North American Cystic Fibrosis Conference

October 23, 2025

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Vertex Pharmaceuticals Inc (NASDAQ:VRTX): A Value Investment Case Study ↗

October 20, 2025

Vertex Pharmaceuticals (VRTX) presents a value investing case with strong profitability, a debt-free balance sheet, and a valuation that appears attractive relative to its industry peers.

Via Chartmill

2 Growth Stocks to Invest $1,000 in Right Now ↗

October 19, 2025

These companies have a habit of beating the market, and they are far from having peaked.

Via The Motley Fool

Topics Artificial Intelligence World Trade

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week

October 17, 2025

From Vertex Pharmaceuticals Incorporated

Via Business Wire

2 Soaring Cathie Wood Stocks to Buy and Hold ↗

October 17, 2025

These companies' market-beating fuel hasn't run out yet.

Via The Motley Fool

Vera Therapeutics' Lead Kidney Drug Poised For 2026 Launch In Multi-Billion-Dollar Market ↗

October 16, 2025

Bank of America initiates coverage on Vera Therapeutics, citing strong potential for atacicept, its kidney treatment.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

72 73 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.